Active surveillance for low-risk prostate cancer: New data on risk factors for switching to active treatment
Review of insurance claims shows how practice behavior changes after approval of durvalumab
10 September 2021Linking US prescription drug prices to those paid in other nations could cut costs in half
10 September 2021Active surveillance for low-risk prostate cancer: New data on risk factors for switching to active treatment
For men with “low-risk” prostate cancer initially managed with active surveillance, cancer-related factors such as tumor grade and size are key risk factors for conversion to active treatment, reports a study in The Journal of Urology, an Official Journal of the American Urological Association (AUA).
